|
Jul 14
|
WHO endorses Gilead’s Yeztugo for HIV prevention
|
|
Jul 14
|
Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025
|
|
Jul 14
|
Biotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.
|
|
Jul 11
|
Sector Update: Health Care Stocks Retreat Late Afternoon
|
|
Jul 11
|
Equity Markets Lower After US Treasury Budget Surplus in June
|
|
Jul 11
|
Guardant Health, Gilead Sciences, Inspire Medical Systems, Enovis, and AMN Healthcare Services Stocks Trade Down, What You Need To Know
|
|
Jul 10
|
Gilead Sciences, Inc. (GILD): A Bull Case Theory
|
|
Jul 10
|
Here's Why Gilead Sciences (GILD) is a Strong Momentum Stock
|
|
Jul 10
|
Morgan Stanley Assumes Coverage of Kymera Therapeutics (KYMR) Stock with Overweight Rating
|
|
Jul 9
|
AHF: Gilead’s Greed Costs Latin America HIV Protection
|
|
Jul 9
|
Gilead Sciences (NasdaqGS:GILD) Partners With Global Fund To Supply HIV Prevention Drug
|
|
Jul 9
|
Gilead Sciences, Inc. (GILD) Reports Advances in HIV Treatment with Phase 2/3 Clinical Trial Update
|
|
Jul 9
|
$14 Billion Cell and Gene Therapy Market to Double by 2030, Driven by Oncology and RNA Breakthroughs, reports Kalorama Information
|
|
Jul 9
|
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
|
|
Jul 9
|
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet
|
|
Jul 9
|
Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
|
|
Jul 8
|
Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?
|
|
Jul 8
|
Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?
|
|
Jul 1
|
Chronic Hepatitis B Market Analysis and Forecast, 2025-2035 | Diagnostic Advances, Innovative Therapies, and Rising Awareness Bolster Growth
|
|
Jun 30
|
Gilead extends gains after Supreme Court upheld an Obamacare provision
|